

Sze, S., Pellicori, P., Zhang, J., Weston, J. and Clark, A. L. (2021) The impact of malnutrition on short-term morbidity and mortality in ambulatory patients with heart failure. *American Journal of Clinical Nutrition*, 113(3), pp. 695-705. (doi: <u>10.1093/ajcn/nqaa311</u>)

The material cannot be used for any other purpose without further permission of the publisher and is for private use only.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

http://eprints.gla.ac.uk/223801/

Deposited on 05 October 2020

Enlighten – Research publications by members of the University of Glasgow <u>http://eprints.gla.ac.uk</u>

1	The impact of malnutrition on short-term morbidity and
2	mortality in ambulatory patients with heart failure
3	Short Title: Prognostic value of malnutrition in heart failure
4	
5	Shirley Sze, MD <sup>1,2</sup> ; Pierpaolo Pellicori, MD, FESC <sup>1,3</sup> ; Jufen Zhang PhD <sup>1,4</sup> ; Joan
6	Weston <sup>1</sup> ; Andrew L Clark, MA, MD, FRCP. <sup>1</sup>
7	
8	<sup>1</sup> Department of Cardiology, Castle Hill Hospital, Hull York Medical School (at
9	University of Hull), Kingston upon Hull, HU16 5JQ, UK
10	<sup>2</sup> NIHR Leicester Biomedical Research Centre, University of Leicester, Glenfield Hospital,
11	Groby Road, Leicester, LE3 9QP
12	<sup>3</sup> Robertson Centre for Biostatistics & Clinical Trials, University of Glasgow
13	<sup>4</sup> School of Medicine, Anglia Ruskin University, CB1 1PT, UK
14	
15	Corresponding author: Shirley Sze
16	NIHR Leicester Biomedical Research Centre, University of Leicester, Glenfield
17	Hospital, Groby Road, Leicester, LE3 9QP, UK, Tel: +44 (0)116 256 3021, Fax: +44
18	(0)116 250 2405
19	Email: <u>Shirley.sze@nhs.net</u>

	Prognostic value of malnutrition in HF April 2020
21	Data described in the manuscript, code book, and analytic code will be made available
22	upon request pending application and approval.
23	Funding/ Sources of support: The authors received no specific funding for this work. No
24	author has received travel, gifts or honoraria associated with any portion of the study.
25	Word count: 3798 (from the introduction to the conclusion, excluding abstract, tables,
26	figures, acknowledgments, references, and supplemental material)
27	
28	Abbreviations: AF = atrial fibrillation, AIC = Akaike Information Criterion, BAPEN =
29	British Association for Parenteral and Enteral Nutrition, BIC = Bayesian Information
30	Criterion, BMI = body mass index, CHF = chronic heart failure, CONUT = controlling
31	nutritional status index, COPD = Chronic obstructive pulmonary disease, CVA =
32	Cerebrovascular accident, eGFR = estimated glomerular filtration rate, GNRI = geriatric
33	nutritional risk index, Hb = hemoglobin, HeFREF = heart failure with reduced ejection
34	fraction, HeFNEF = heart failure with normal ejection fraction, HF = heart failure, IQR=
35	interquartile range, LVEF = left ventricular ejection fraction, MI = myocardial infarction,
36	MNA-SF = mini nutritional assessment-short form, MUST = malnutrition universal screening
37	tool, NT-proBNP = N-terminal pro B-type natriuretic peptide, NYHA = New York Heart
38	Association, PNI = prognostic nutritional index, PVD = peripheral vascular disease, SGA =
39	subjective global assessment.

44	
45	Abstract:
46	Background:
47	Malnutrition is common in patients with chronic heart failure (CHF) and is associated with
48	adverse outcome, but it is uncertain how malnutrition should best be evaluated.
49	
50	Objectives:
51	This prospective cohort study aims to compare the short-term prognostic value of 9
52	commonly used malnutrition tools in CHF patients.
53	
54	Methods:
55	We assessed, simultaneously: 3 simple tools (controlling nutritional status (CONUT) score,
56	geriatric nutritional risk index (GNRI), prognostic nutritional index (PNI)); 3 multi-
57	dimensional tools (malnutrition universal screening tool (MUST), mini nutritional
58	assessment-short form (MNA-SF), subjective global assessment (SGA)); and 3 laboratory
59	tests (serum cholesterol, albumin and total lymphocyte count) in consecutive patients with
60	CHF attending a routine follow-up. The primary end point was all-cause mortality; the
61	secondary end point was the combination of all-cause hospitalization and all-cause mortality.
62	
63	Results:
64	467 patients (67% male, median age 76 years (range: 21-98 years), median N-terminal pro-B-
65	type natriuretic peptide (NT-proBNP) 1156 ng/L) were enrolled. During a median follow-up
66	of 554 days, 82 (18%) patients died and 201 (43%) patients had either a non-elective
67	hospitalization or died.

April 2020

69	In models corrected for age, hemoglobin (Hb), renal function, New York Heart Association
70	(NYHA) class, NTproBNP, body mass index and comorbidities, all malnutrition tools, except
71	total lymphocyte count and serum cholesterol, were independently associated with worse
72	morbidity and mortality.
73	
74	A base model for predicting mortality including age, NYHA class, log [NT-proBNP], Hb,
75	renal function and comorbidities had a C-statistic of 0.757. Among simple tools: CONUT (C-
76	statistic=0.777); among multi-dimensional tools, MNA-SF (C-statistic=0.776) and among
77	biochemical tests: albumin (C-statistic=0.773), increased model performance most compared
78	to base model. Patients with serum albumin <30 g/L was associated with a 6-fold increase in
79	mortality compared to patients with albumin $\geq$ 35 g/L.
80	
81	Conclusion:
82	Malnutrition is strongly associated with adverse outcomes in CHF patients. Measuring serum
83	albumin provides comparable prognostic information to simple or multi-dimensional
84	malnutrition tools.
85	(300 words)
86	
87	
88	Key words: heart failure, malnutrition, prognosis, mortality, hospitalization
89	
90	
91	
92	

April 2020

# 94 Introduction:

Malnutrition is the lack of intake or uptake of nutrients, which ultimately results in altered
body composition, leading to reduced physical function and worse clinical outcomes (1).

98	Malnutrition is common in patients with heart failure (HF), and is associated with significant
99	disability, morbidity and mortality (2). The relationship between malnutrition and HF is
100	complex. On one hand, nutritional deficiencies might cause atrophy and fibrosis of cardiac
101	myocytes, leading to reduced left ventricular mass and function (3,4). The lack of nutrients
102	secondary to poor lifestyles and habits such as chronic and severe alcoholism, might also
103	contribute to the development of overt HF. On the other hand, HF itself predisposes to
104	congestive enteropathy and malabsorption (5). The sustained neurohormonal activation and
105	chronic inflammation associated with HF lead to hypercatabolism, which, in turn, predisposes
106	to sarcopenia and cachexia (6). Older age, polypharmacy, and other co-morbidities, such as
107	dementia or frailty (7), might further increase the risk of malnutrition in patients with HF.
108	
109	Current guidelines recommend assessment of nutritional status in patients with HF(8), but
110	there is no consensus as to how malnutrition should best be measured. We therefore
111	performed a comprehensive malnutrition evaluation in a cohort of well-characterised
112	ambulatory patients with chronic heart failure (CHF) and compared the short-term prognostic
113	significance of 9 commonly used malnutrition tools.
114	
115	Methods
116	Study population (Supplementary Figure 1)

117 Between September 2016 and March 2017, we enrolled prospectively consecutive

ambulatory patients with CHF who attended a community HF clinic for a routine follow-up

April 2020

119	appointment. All patients had a pre-existing (>1 year) clinical diagnosis of HF, confirmed by
120	either evidence of left ventricular systolic dysfunction on echocardiography (left ventricular
121	ejection fraction (LVEF) <40% or at least moderate left ventricular systolic dysfunction by
122	visual inspection if LVEF was not calculated), defined as heart failure with reduced ejection
123	fraction, HeFREF; or normal left ventricular systolic function (LVEF $\geq$ 40%) and N-terminal
124	pro-B-type natriuretic peptide (NTproBNP) >400 ng/L, defined as heart failure with normal
125	ejection fraction, HeFNEF (9). All patients gave consent to take part in research and had been
126	initiated on treatment for HF according to the Heart Failure Association of the European
127	Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart
128	failure (8).
129	
130	During the visit, all patients had a full medical history, physical examination, blood tests (full
131	blood count, urea and electrolytes and NT-proBNP), an electrocardiogram and a consultation
132	with a HF specialist.
133	
134	Malnutrition evaluation
135	All patients were screened by the same researcher (SS) for malnutrition. (Supplementary
136	Table 1a)
137	The simple tools used were:
138	1) The geriatric nutritional risk index (GNRI)
139	GNRI was calculated using the formula: [1.489 x albumin (g/L)] + [41.7 x current weight/
140	ideal weight] (10). Ideal body weight was calculated using the formula: 22 x square of height
141	in meters (11). Subjects with GNRI >98 have normal nutritional status, those with GNRI 92-
142	98, 82-91, <82 have mild, moderate and severe malnutrition respectively. GNRI $\leq$ 98 is
143	classified as malnourished (10).

April 2020

1	Δ	Δ
т	т	-

145	<i>2) The COntrolling NUTritional Status index</i> (CONUT score; scored between 0-12):
146	The CONUT score was developed by Ignacio de Ulibarri and colleagues in 2005 as a
147	screening tool for assessment of nutritional status of in-patients (12). It uses serum albumin,
148	cholesterol and total lymphocyte count. Subjects with a CONUT score 0-1 have normal
149	nutritional status, those with CONUT score 2-4, 5-8, 9-12 have mild, moderate and severe
150	malnutrition respectively. Subjects with CONUT score $\geq 2$ are classified as malnourished
151	(12).
152	
153	<i>3) The prognostic nutritional index</i> (PNI)
154	PNI is calculated using the formula: 10 x serum albumin $(g/dL) + 0.005$ x total lymphocyte
155	count (mm <sup><math>3</math></sup> ) (13). Subjects with PNI >38 have normal nutritional status; those with PNI 35-
156	38 and <35 have moderate and severe malnutrition respectively. Subjects with PNI $\leq$ 38 are
157	classified as malnourished (13).
158	
159	The multi-dimensional tools used were:
160	<i>1) Malnutrition Universal Screening Tool (</i> MUST; scored between 0-2): (Supplementary
161	Table 1b)
162	MUST is a screening tool developed by the multidisciplinary malnutrition advisory group of
163	the British Association for Parenteral and Enteral Nutrition (BAPEN) in 2003 to identify
164	malnutrition in adults (14). MUST uses 3 simple steps: body mass index (BMI), weight loss
165	and the effect of acute illness on food intake to generate an overall risk of malnutrition.
166	Subjects with MUST score 0 have normal nutritional status (low malnutrition risk); those
167	with MUST score 1 and $\geq$ 2 have mild (medium risk) and $\geq$ moderate (high risk) malnutrition
168	respectively. Subjects with $MUST \ge 1$ are classified as malnourished (14). The researcher

April 2020

169 who assessed nutrition status completed the BAPEN's e-learning available at

- 170 www.bapen.org.uk.
- 171

172 2) *Mini Nutritional Assessment Short Form* (MNA-SF; scored between 0-14):

- 173 (Supplementary Table 1c)
- 174 MNA was developed in 1996 as a tool to identify malnutrition in elderly patients (15). MNA-

175 short form (MNA-SF) (16), a shorter version of MNA, consists of 6 questions which assess

176 food intake, weight loss, mobility, acute events, neuro-psychological problems and BMI.

177 Subjects with MNA-SF score 12-14 have normal nutritional status, those with MNA-SF score

178 8-11 and  $\leq$ 7 have mild and  $\geq$  moderate malnutrition respectively. Subjects with MNA-SF

- 179 score  $\leq 11$  are classified as malnourished (16).
- 180

181 3) Subjective global assessment (SGA; scored as A, B or C): (Supplementary Table 1d) 182 SGA is a nutritional assessment tool that is widely used in a variety of clinical settings 183 (17,18). It includes an assessment of medical history (specifically evaluating weight loss, 184 changes in dietary intake, gastrointestinal symptoms and functional capacity) and a physical 185 examination (specifically evaluating large muscle wasting as determined by palpable loss of 186 bulk; subcutaneous fat loss as determined by arm circumference; peripheral edema and 187 ascites: graded as none; mild to moderate or severe). The measurements are not precise, but 188 are a subjective impression. Each component of the SGA is ranked as either 'A', 'B' or 'C' 189 according to specific set criteria, with 'A' reflecting normal nutritional status and 'C' 190 reflecting significant malnutrition. The ranking with the highest frequency among individual 191 components of SGA was determined as the overall SGA score. We classified subjects with 192 SGA- A as having normal nutritional status, those with SGA-B and C, we classified as

- having mild and  $\geq$  moderate malnutrition respectively. Subjects with SGA-B or C are
- 194 malnourished (17).
- 195

196 The laboratory tests chosen were based on the components of the CONUT score as these

- 197 have been studied in prior work (19):
- 198 1) Serum cholesterol level (mmol/L): (Supplementary Table 1a)
- 199 Subjects with serum cholesterol level >4.65 have normal nutritional status according to the
- 200 CONUT score cut-off, those with serum cholesterol level 3.62-4.65, 2.59-3.61, <2.59 have
- 201 mild, moderate and severe malnutrition respectively (12). Subjects with serum cholesterol
- 202 level  $\leq$  4.65 are classified as malnourished.
- 203 2) Serum albumin level (g/L): (Supplementary Table 1a)
- 204 Subjects with serum albumin level  $\geq$ 35 have normal nutritional status according to the
- 205 CONUT score cut-off, those with serum albumin level 30-34, 25-29 and <25 have mild,
- 206 moderate and severe malnutrition respectively (12). Subjects with serum albumin level <35
- are classified as malnourished.
- 208 3) Serum total lymphocyte count  $(x10^9/L)$ : (Supplementary Table 1a)
- 209 Subjects with serum total lymphocyte count of  $\geq$ 1.6 have normal nutritional status according
- to the CONUT score cut-off, those with total lymphocyte count 1.20-1.59, 0.80-1.19 and
- 211 <0.80 have mild, moderate and severe malnutrition respectively (12). Subjects with serum
- total lymphocyte count <1.6 are classified as malnourished.
- 213

# 214 <u>Co-morbidities</u>

215	Co-morbidities were recorded using the Charlson co-morbidity index/score (20).
216	Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure
217	≥90 mmHg or a previous clinical diagnosis (21). Current hemoglobin (Hb) levels were used
218	to define anemia (Hb<13.0 g/dL in men and <12.0 g/dL in women) (22). Diabetes mellitus
219	was defined according to the Diabetes UK guidelines (23). Patients consented to the use of
220	electronic medical records to identify previous clinical history of myocardial infarction (MI),
221	peripheral vascular disease (PVD), cerebrovascular accidents (CVA), chronic obstructive
222	pulmonary disease (COPD), dementia, rheumatological disease, peptic ulcer disease, liver or
223	renal disease or malignancy.
224	
225	
226	End points and follow-up
227	Patients were followed until the 1 <sup>st</sup> of August 2018. All patients were followed for a
228	minimum of one year. The primary end point was all-cause mortality and the secondary end
229	point was the combination of all-cause hospitalization and all-cause mortality.
230	
231	Mortality was ascertained by using medical records (updated systematically onto a NHS
232	electronic database), autopsy reports and death certificates. Hospitalization was ascertained
233	by using electronic medical records and discharge letters. Hospitalizations refer to non-
234	elective admissions to hospital with length of stay of at least 24 hours.
235	
236	Statistical analysis
237	Continuous data are expressed as a median with interquartile range (IQR) (25 <sup>th</sup> to
238	$75^{\text{th}}$ centiles) and categorical data are expressed as % (N). Independent t tests and Mann-
239	Whitney U tests were used to compare two continuous variables for normally and non-

April 2020

normally distributed data. The chi-squared test was used to compare proportions betweengroups.

242

243	Time-to-event data are presented graphically using Kaplan-Meier curves. Log-rank-tests were
244	used to compare survival between groups. To understand the prognostic value of different
245	malnutrition tools, we performed two types of analyses: 1) etiological analysis and 2)
246	predictive analysis. <sup>24</sup> The aim of the etiological analysis is to understand the causal
247	relationship between malnutrition tools and outcomes, with adjustment for possible
248	confounders. On the other hand, the aim of the predictive analysis is to predict accurately the
249	risk of outcomes using multiple predictors collectively.
250	
251	For etiological analysis, the relation between a variable and outcome was explored using Cox
252	regression analysis. The Schoenfeld and scaled Schoenfeld residuals were used to check the
253	proportional hazards assumption in multivariable Cox regression analyses (Supplementary
254	Table 2). Since there is no significant relationship between residuals and time, we assumed
255	the proportional hazards (Supplementary Figure 2). Univariable and multivariable analyses
256	with Cox proportional hazard regression were used to determine significant predictors of
257	events. Variables with p<0.05 in univariable analysis, which are known predictors of
258	outcomes in patients with HF, were entered into a multivariable analysis with each
259	malnutrition tool both as a continuous and binary variable. In order to determine accurately
260	the association between malnutrition tools and outcomes, multivariable adjustment was
261	performed for the following variables: age, BMI, cardiac rhythm [atrial fibrillation (AF) vs
262	sinus rhythm], New York Heart Association (NYHA) class (III/IV vs I/II), Charlson score,
263	log[NTproBNP], Hb and estimated glomerular filtration rate (eGFR). Potential effect-
264	modification was tested by fitting models containing both main effects and their cross-

April 2020

265	product terms. Specifically, effect-modification was tested between the following variables:
266	age and BMI; age and cardiac rhythm; age and NYHA class; age and log[NTproBNP]; age
267	and Charlson score; age and Hb; age and eGFR; malnutrition tool and age; malnutrition tool
268	and BMI; malnutrition tool and cardiac rhythm; malnutrition tool and NYHA class;
269	malnutrition tool and log[NTproBNP]; malnutrition tool and Charlson score; malnutrition
270	tool and Hb; and malnutrition tool and eGFR in multivariable Cox regression analysis for
271	predicting all-cause mortality (Supplementary Table 3). Further analyses were performed to
272	study the relationship between the degree of malnutrition and outcome. We used the
273	malnutrition tool from each category (simple tools, multi-dimensional tools and single
274	laboratory test) which best predicted all-cause mortality (highest Wald $\chi^2$ ). Log-
275	transformation was applied when the data were very right-skewed.
276	
277	For predictive analysis, in order to compare the performance of different malnutrition tools in
278	predicting outcomes, we created a common base model including age, NYHA class (III/IV vs
279	I/II), log [NT-proBNP], Hb, eGFR, AF, CVA and COPD for predicting mortality. These
280	variables are all significant predictors of mortality in univariable Cox regression analysis.
281	The base model was standardised so that a fair comparison can be made regarding the
282	prognostic performance of different malnutrition tools. Although BMI, dementia and falls
283	were significant univariable predictors of mortality, they were excluded from the base model
284	as they are contained in some of the malnutrition tools. We added each of the malnutrition
285	tools in turn to the base model and used Harrell's C-statistic to evaluate model discrimination
286	in survival analysis. A C-statistic of 0.5 indicates no discriminative ability at all while a C-
287	statistic of 1 indicates perfect discrimination. The likelihood ratio was used to determine if
288	there was any significant difference in model fit between the base model and models
289	including different malnutrition tools. We performed additional sensitivity analyses where we

April 2020

290	constructed different base models for evaluating the prognostic performance of different
291	malnutrition tools, based on the components of each tool (Supplementary Table 4). To
292	compare the prognostic performance of models including different malnutrition tools, we
293	used the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). The
294	lower the AIC or BIC value, the better the model fit (Supplementary Table 5).
295	To evaluate length of stay during hospitalization, we only included patients with at least one
296	hospitalization and hospitalizations resulting in death were excluded.
297	
298	All statistical analyses were performed using SPSS 26 (SPSS INc., Chicago, IL, USA) and
299	The Stata (14th Version, StataCorp, TX, USA) statistical computer package. A two-tailed P-
300	value of <0.05 was considered significant in all analyses.
301	
302	The study conformed to the principles outlined in the Declaration of Helsinki and was
303	approved by relevant ethical bodies. All subjects gave their written informed consent for their
304	data to be used for research.
305	
306	
307	Results
308	A total of 467 consecutive ambulatory patients with HF was approached and all patients
309	consented to participate in the study. No patient was lost to follow up as we regularly receive
310	information on admissions and deaths from the two regional hospitals which provide
311	emergency care, in turn linked with our research database.
312	
313	Baseline characteristics

April 2020

The majority of patients were male and elderly; most patients had HeFREF (62%) with

median NT-proBNP of 1156 (496-2463) ng/L; around 20% had severe symptoms (NYHA
class III/IV). (Table 1)

317

318 Compared to patients who were alive at 1 year, those who died were older, had more severe

319 symptoms and were more likely to be malnourished at baseline. They also had higher NT-

320 proBNP levels, lower BMI and more co-morbidities. (Table 1)

321

# 322 Relation between malnutrition and mortality

323 During a median follow-up of 554 days (interquartile range 511-629 days), 18% of patients

324 died. The influence of malnutrition measures considered as univariable predictors of

325 mortality are shown in Supplementary Table 6a with Supplementary Table 6b showing the

326 results for other clinical variables. The presence of malnutrition, as determined by any tool,

327 was associated with increased risk of mortality. Clinical variables included in multivariable

328 analyses for predicting mortality are shown in Supplementary Table 7. All malnutrition tools,

329 with the exception of total lymphocyte count, and GNRI, PNI and MUST score as binary

330 variables, were significant predictors of all-cause mortality when evaluated individually in

331 multivariable analysis (Table 2).

332

333 A base model (including age, NYHA (III/IV vs I/II), log [NT-proBNP], Hb, eGFR, AF, CVA

and COPD) for predicting mortality achieved a C-statistic of 0.757 (Table 3). Each

335 malnutrition tool, when added individually, except total lymphocyte count, led to better

336 model fit compared to the base model. Among the simple tools: CONUT score (C-

statistic=0.777); among the multi-dimensional tools: MNA-SF (C-statistic=0.776); and

338	among the single laboratory tests: albumin (C-statistic=0.773), all as continuous variables,
339	increased model performance most compared with base model.
340	
341	Patients who were at least moderately malnourished according to CONUT score, MNA-SF
342	and albumin, had a 6-10 times greater mortality risk than those who were not malnourished.
343	(Figure 1)
344	
345	The 3-month, 6-month and 12-month mortality according to worsening malnutrition
346	categories is shown in Figure 2, top panel. Patients with the worst nutritional status, had a
347	much higher 1-year mortality rate (33-47%) than patients with the best nutritional status (2-
348	4%).
349	
350	
350 351	Relation between malnutrition and combined all-cause hospitalization and mortality
	<b>Relation between malnutrition and combined all-cause hospitalization and mortality</b> During follow up, 43% of patients were either hospitalised or died. The influence of
351	
351 352	During follow up, 43% of patients were either hospitalised or died. The influence of
351 352 353	During follow up, 43% of patients were either hospitalised or died. The influence of malnutrition measures considered as univariable predictors of the combined outcome are
<ul><li>351</li><li>352</li><li>353</li><li>354</li></ul>	During follow up, 43% of patients were either hospitalised or died. The influence of malnutrition measures considered as univariable predictors of the combined outcome are shown in Supplementary Table 6a with Supplementary Table 6b showing the results for other
<ul> <li>351</li> <li>352</li> <li>353</li> <li>354</li> <li>355</li> </ul>	During follow up, 43% of patients were either hospitalised or died. The influence of malnutrition measures considered as univariable predictors of the combined outcome are shown in Supplementary Table 6a with Supplementary Table 6b showing the results for other clinical variables. The presence of malnutrition, as determined by any malnutrition tool, was
<ul> <li>351</li> <li>352</li> <li>353</li> <li>354</li> <li>355</li> <li>356</li> </ul>	During follow up, 43% of patients were either hospitalised or died. The influence of malnutrition measures considered as univariable predictors of the combined outcome are shown in Supplementary Table 6a with Supplementary Table 6b showing the results for other clinical variables. The presence of malnutrition, as determined by any malnutrition tool, was associated with increased risk of combined outcome. Clinical variables included in
<ul> <li>351</li> <li>352</li> <li>353</li> <li>354</li> <li>355</li> <li>356</li> <li>357</li> </ul>	During follow up, 43% of patients were either hospitalised or died. The influence of malnutrition measures considered as univariable predictors of the combined outcome are shown in Supplementary Table 6a with Supplementary Table 6b showing the results for other clinical variables. The presence of malnutrition, as determined by any malnutrition tool, was associated with increased risk of combined outcome. Clinical variables included in multivariable analysis for predicting combined outcome are shown in Supplementary Table 7.
<ul> <li>351</li> <li>352</li> <li>353</li> <li>354</li> <li>355</li> <li>356</li> <li>357</li> <li>358</li> </ul>	During follow up, 43% of patients were either hospitalised or died. The influence of malnutrition measures considered as univariable predictors of the combined outcome are shown in Supplementary Table 6a with Supplementary Table 6b showing the results for other clinical variables. The presence of malnutrition, as determined by any malnutrition tool, was associated with increased risk of combined outcome. Clinical variables included in multivariable analysis for predicting combined outcome are shown in Supplementary Table 7. All malnutrition tools, with the exception of total lymphocyte count and serum cholesterol

April 2020

362	Patients who were at least moderately malnourished according to CONUT score, MNA-SF
363	and albumin, had a 5-11 times greater risk of combined outcome than those who were not
364	malnourished (Figure 3).
365	
366	The 3-month, 6-month and 12-month combined event rates according to malnutrition
367	categories is shown in Figure 2, bottom panel. Patients with the worst nutritional status, had a
368	much higher 3-month combined event rate (27-47%) than patients with the best nutritional
369	status (5-8%). A similar trend was seen in 6-month and 12-month combined event rates.
370	
371	The relation between malnutrition and all-cause hospitalization alone is shown in
372	supplementary tables 8-9.
373	
374	Discussion
374 375	<b>Discussion</b> Our study is the first to comprehensively compare the prognostic value of several commonly
375	Our study is the first to comprehensively compare the prognostic value of several commonly
375 376	Our study is the first to comprehensively compare the prognostic value of several commonly used malnutrition tools in a well-characterised cohort of ambulatory patients with CHF. In
375 376 377	Our study is the first to comprehensively compare the prognostic value of several commonly used malnutrition tools in a well-characterised cohort of ambulatory patients with CHF. In order to eliminate possible bias regarding time between HF diagnosis and enrollment on the
<ul><li>375</li><li>376</li><li>377</li><li>378</li></ul>	Our study is the first to comprehensively compare the prognostic value of several commonly used malnutrition tools in a well-characterised cohort of ambulatory patients with CHF. In order to eliminate possible bias regarding time between HF diagnosis and enrollment on the association between malnutrition and outcomes, we recruited consecutive ambulatory patients
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> </ul>	Our study is the first to comprehensively compare the prognostic value of several commonly used malnutrition tools in a well-characterised cohort of ambulatory patients with CHF. In order to eliminate possible bias regarding time between HF diagnosis and enrollment on the association between malnutrition and outcomes, we recruited consecutive ambulatory patients who attended our HF clinic for a routine follow up appointment. All patients had a pre-
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> </ul>	Our study is the first to comprehensively compare the prognostic value of several commonly used malnutrition tools in a well-characterised cohort of ambulatory patients with CHF. In order to eliminate possible bias regarding time between HF diagnosis and enrollment on the association between malnutrition and outcomes, we recruited consecutive ambulatory patients who attended our HF clinic for a routine follow up appointment. All patients had a pre- existing clinical diagnosis of HF for at least one year and all have been started on guideline-
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> </ul>	Our study is the first to comprehensively compare the prognostic value of several commonly used malnutrition tools in a well-characterised cohort of ambulatory patients with CHF. In order to eliminate possible bias regarding time between HF diagnosis and enrollment on the association between malnutrition and outcomes, we recruited consecutive ambulatory patients who attended our HF clinic for a routine follow up appointment. All patients had a pre- existing clinical diagnosis of HF for at least one year and all have been started on guideline- indicated HF treatment. From etiological analyses, we found that malnutrition as determined
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> <li>382</li> </ul>	Our study is the first to comprehensively compare the prognostic value of several commonly used malnutrition tools in a well-characterised cohort of ambulatory patients with CHF. In order to eliminate possible bias regarding time between HF diagnosis and enrollment on the association between malnutrition and outcomes, we recruited consecutive ambulatory patients who attended our HF clinic for a routine follow up appointment. All patients had a pre- existing clinical diagnosis of HF for at least one year and all have been started on guideline- indicated HF treatment. From etiological analyses, we found that malnutrition as determined by any malnutrition tools as a continuous variable except total lymphocyte count and serum
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> <li>382</li> <li>383</li> </ul>	Our study is the first to comprehensively compare the prognostic value of several commonly used malnutrition tools in a well-characterised cohort of ambulatory patients with CHF. In order to eliminate possible bias regarding time between HF diagnosis and enrollment on the association between malnutrition and outcomes, we recruited consecutive ambulatory patients who attended our HF clinic for a routine follow up appointment. All patients had a pre-existing clinical diagnosis of HF for at least one year and all have been started on guideline-indicated HF treatment. From etiological analyses, we found that malnutrition as determined by any malnutrition tools as a continuous variable except total lymphocyte count and serum cholesterol level, was associated with worse morbidity and mortality, after adjustment for

386 outcome (25). From predictive analyses, we found that malnutrition as determined by any

April 2020

388 age, NYHA (III/IV vs I/II), log [NT-proBNP], Hb, eGFR, AF, CVA and COPD, for 389 predicting mortality, although the degree of improvement is small. This is likely due to the 390 fact that malnutrition is associated with variables forming the base model, such as increasing 391 age, worsening HF and complex comorbidities. (26) 392 393 It is important to distinguish between analyses performed using an etiological versus a 394 predictive approach. (24) Although both approaches make use of multivariable modelling, the 395 underlying research aim and interpretation of results are different. We performed etiological 396 analyses to determine the effect of malnutrition on outcomes after adjusting for confounders. 397 On the other hand, predictive analyses aim at predicting accurately the risk of mortality using 398 a combination of factors. The final prediction model is based on statistical significance and 399 not necessarily causal associations.

tool apart from total lymphocyte count, improved the performance of a base model including

400

387

401 Many novel malnutrition tools incorporating different combinations of clinical and 402 biochemical factors have been developed and are strong predictors of adverse outcomes (2). 403 However, the impact of individual factors on the overall prognostic performance of 404 combination tools is unclear. Up to 25% of ambulatory patients with HF have 405 hypoalbuminemia, and the proportion is greater among those requiring recurrent 406 hospitalizations. We found that serum albumin has a similar prognostic value as the more 407 complex malnutrition tools. Albumin may reflect the overall clinical status of patients with 408 HF. Apart from being a marker of malnutrition, albumin levels can fluctuate with acute 409 illness, congestion or liver dysfunction, all of which are common in patients with HF and 410 predispose to malnutrition via mechanisms such as bowel congestion, increased basal 411 metabolism or reduced dietary intake. Given its simplicity and easy accessibility, albumin

412 may be useful as a screening tool of patients at risk of malnutrition who may benefit from413 more detailed nutrition assessment.

414

415	Simple malnutrition tools such as the CONUT score, GNRI and PNI, measure malnutrition
416	using a combination of laboratory tests and anthropometric measures in addition to albumin.
417	They can generally be completed within a minute. The CONUT score uses serum albumin,
418	cholesterol and lymphocyte count. Its use in patients with HF is potentially limited by statin
419	use. PNI only classifies patients as either non-malnourished or at least moderately
420	malnourished, and therefore underestimates the prevalence of milder degrees of malnutrition.
421	GNRI takes into account weight, which might be confounded by fluid status, and
422	underestimate malnutrition in obese patients (27).
423	
424	Multi-dimensional tools, such as MUST score, MNA-SF and SGA, offer a more
425	comprehensive approach to assess nutritional status by taking into account a variety of
426	clinical and dietary factors, but have subjective components and are time-consuming to
427	perform (5-20 minutes, depending on mobility of patients). A recent systematic review which
428	included 28 observational studies on malnutrition tools and clinical outcomes in patients with
429	stable or acute HF, concluded that among 11 malnutrition tools, MNA has the best predictive
430	ability for mortality (2). However, the reliability of these results is limited as they were
431	generated from a meta-analysis of observational studies investigating different malnutrition
432	tools.
433	
434	The pathophysiology of malnutrition in patients with HF is not well understood. Several
435	theories have been proposed. One possibility is that fluid retention might cause gut edema

436 leading to nausea, anorexia and possibly malabsorption (28). A second possibility is that

April 2020

change in gut morphology and function disrupts the immunological barrier of the bowel wall,
triggering release of pro-inflammatory cytokines. Chronic inflammation and neurohormonal
activation in HF also promote catabolism, leading to protein and fat tissue degradation, and
thus weight loss and cachexia (27,29).

441

442 Malnutrition predisposes to cachexia which is associated with functional impairment, reduced 443 quality of life, increased morbidity and mortality (30). Early identification of malnutrition in 444 patients with HF may allow initiation of potential treatment to prevent the development of 445 cachexia. Firstly, optimisation of HF therapy might help stabilise systemic haemodynamics 446 and improve bowel edema (31). Secondly, regular nutritional counselling and promotion of a 447 high caloric and high protein diet might help ensure adequate dietary intake (31). 448 Micronutrient and vitamin supplementation might also be helpful (31,32). Regular physical 449 exercise has anti-inflammatory effect and might ameliorate progressive tissue wasting (31). 450 Other mechanistically appealing treatments include appetite stimulants, anti-inflammatory 451 agents and anabolic hormones, but their role in the treatment of malnutrition is unclear (30).

452

#### 453 Study limitations

This is a single-centre study conducted in the UK with limited sample size, and so external validation of our results from other populations with different healthcare and social systems

456 is needed. Secondly, we have limited follow up. We are unable to comment on long-term

457 prognostic significance of malnutrition in the HF population. However, the majority of

458 patients identified as malnourished had had an end-point by the end of the study. Thirdly, we

did not study the change in nutritional status over time. Lastly, the type I error rate of the Cox

460 regression analyses may be increased due to multiple testing.

461

April 2020

#### 462 **Conclusions**

- 463 Malnutrition, measured by any of the malnutrition tools studied, with the exception of total
- 464 lymphocyte count and serum cholesterol level, is a strong predictor of morbidity and
- 465 mortality in stable ambulatory patients with CHF. Measuring serum albumin provides
- 466 comparable prognostic information to simple or multi-dimensional malnutrition tools.

- 468 Acknowledgement: This research was supported by the NIHR Leicester Clinical Research
- 469 Facility. The views expressed are those of the authors and not necessarily those of the NHS,
- 470 the NIHR or the Department of Health and Social Care.
- 471 **Conflict of interest:** Dr Shirley Sze, no conflict of interest. Dr Pierpaolo Pellicori, no
- 472 conflict of interest. Dr Jufen Zhang, no conflict of interest. Ms Joan Weston, no conflict of
- 473 interest. Professor Andrew Clark, no conflict of interest.
- 474 Statement of authors' contributions to manuscript: SS, PP and ALC designed
- 475 research; SS, PP and JW conducted research; SS, PP and JZ analysed data; SS wrote paper;
- 476 PP, JZ, JW and ALC reviewed paper. All authors have read and approved the final
- 477 manuscript.

#### References

1 Cederholm R, Barazzoni P, Austin P, Ballmer P, Biolo G, Bischoff SC, Compher C, Correia I, Higashiguchi T, Holst M, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. *Clin Nutr.* 2017; **36**: 49-64,

2 Lin H, Zhang H, Lin Z, Li X, Kong X and Sun G. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. *Heart Fail Rev.* 2016;**21**:549-565.

3 Di Gioia G, Creta A, Fittipaldi M, Giorgino R, Quintarelli F, Satriano U, Cruciani

A, Antinolfi V, Di Berardino S, Costanzo D, et al. Effects of Malnutrition on Left Ventricular Mass in a North-Malagasy Children Population. *PLoS One* 2016;**11:**e0154523

4 Faddan NHA, Sayh KIE, Shams H, Badrawy H. Myocardial dysfunction in malnourished children. *Ann Pediatr Cardiol* 2010;**3**:113-18

5 Valentova M, von Haehling S, Bauditz J, Doehner W, Ebner N, Bekfani T, Elsner S, Sliziuk V, Scherbakov N, Murín J, et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. *Eur Heart J* 2016;**37:**1684-91

6 von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. *Cardiovasc Res* 2007;**73**:298-309
7 Fávaro-Moreira NC, Krausch-Hofmann S, Matthys C, Vereecken C, Vanhauwaert E, Declercq A, Bekkering GE, Duyck J. Risk Factors for Malnutrition in Older Adults: A Systematic Review of the Literature Based on Longitudinal Data. *Adv Nutr* 2016;**7**:507-22
8 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, et al; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure of

the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;**18**:891-975 9 National Institute for Health and Care Excellence (2018). Chronic heart failure in adults: diagnosis and management. [Accessed April 2019] available at: https://www.nice.org.uk/guidance/NG106

10 Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, Benazeth S, Cynober L, Aussel C. Geriatric nutritional risk index: a new index for evaluating at –risk elderly medical patients. *Am J Clin Nutr* 2005;**82**:777-83.

11 Cereda E, Pedrolli G. The geriatric nutritional risk index. *Curr Opin Clin Nutr Metab Care* 2009;**12**:1-7.

12 Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, González P, González
B, Mancha A, Rodríguez F, Fernández G. CONUT: a tool for controlling nutritional status.
First validation in a hospital population. *Nutr Hosp* 2005; 20:38-45.

13 Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato EF. Prognostic nutritional index in gastrointestinal surgery. *Am J Surg* 1980;**139**:160–167.

14 Elia M, The British Association for Parenteral and Enteral Nutrition: Malnutrition Advisory Group. The 'MUST' Report. Nutritional screening of adults: a multidisciplinary responsibility. Last modified. 2003. Accessed 22.7.2019. https://www.bapen.org.uk/pdfs/must/must-report.pdf

15 Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. *Nutr Rev.* 1996;**54**:59-65.

16 Rubenstein LZ, Harker JO, Salva A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the Short-Form Mini-Nutritional Assessment (MNA-SF). *J. Gerontol.* 2001;**56**: M366–M372.

17 Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, MendelsonRA, Jeejeebhoy KN. What is subjective global assessment of nutritional status? *J ParenterEnteral Nutr* 1987;11:8 13.

18 da Silva Fink J, Daniel de Mello P, Daniel de Mello E. Subjective global assessment of nutritional status – A systematic review of the literature. *Clin Nutr*. 2015;**34**:785-92.

19 Mizobuchi K, Jujo K, Minami Y, Ishida I, Nakao M, Hagiwara N. The baseline nutritional status predicts long term mortality in patients undergoing endovascular therapy. *Nutrients* 2019;**11:**1745.

20 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;**40**:373-383.

21 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;**289**:2560–72.

22 Janz TG, Johnson RL, Rubenstein SD. Anemia in the emergency department: evaluation and treatment. *Emergency Medicine Practice*.2013;**15**:1-15.

23 Diagnostic criteria for diabetes. Diabetes UK. URL:

https://www.diabetes.org.uk/Professionals/Position-statements-reports/Diagnosis-ongoingmanagement-monitoring/New\_diagnostic\_criteria\_for\_diabetes/ (Last accessed on 27th June 2017)

24 van Diepen M, Ramspek CL, Jager KJ, Zoccali C, Dekker FW. Prediction versus aetiology: common pitfalls and how to avoid them. *Nephrol Dial Transplant*.

2017;32(suppl\_2):ii1-ii5.

25 Wawrzenczyk A, Anaszewicz M, Wawrzenczyk A, Budzynski J. Clinical significance of nutritional status in patients with chronic heart failure-a systematic review. *Heart Fail Rev* 2019. doi: 10.1007/s10741-019-09793-2

26 Sze S, Pellicori P, Zhang J, Weston J, Clark AL. Agreement and Classification
Performance of Malnutrition Tools in Patients with Chronic Heart Failure. *Curr Dev Nutr*.
2020;4(6):nzaa071.

27 Sze S, Pellicori P, Kazmi S, Rigby A, Cleland JGF, Wong K, Clark AL. Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure: A Comparison With Body Mass Index. *JACC Heart Fail* 2018;6:476-86
28 Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. *Heart*. 2004; 90:464–470.

29 Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson

PA, Coats AJ. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. *Circulation*. 1997; **96**:526–534.

30 Rahman A, Jafry S, Jeejeebhoy K, Nagpal AD, Pisani B, Agarwala R. Malnutrition and cachexia in heart failure. *JPEN J Parenter Enteral Nutr* 2016;**40**:475-86

31 Azhar G, Wei JY. New Approaches to Treating Cardiac Cachexia in the Older Patient. *Curr Cardiovasc Risk Rep.* 2013;7:480–484. 32 Witte KK, Nikitin NP, Parker AC, von Haehling S, Volk HD, Anker SD, Clark

AL, Cleland JG. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. *Eur Heart J* 2005;**26:**2238-44.

	HF patients N=467	Died by 1 year N=56	Alive at 1 year N=411	P (Died vs	Missing
		N 50	14 411	alive)	
Demographics					
Age	76 (69-82)	82 (77-87)	75 (68-82)	< 0.001	0
Sex (male), % (N)	67 (313)	68 (38)	67 (275)	0.88	0
HR (bpm)	70 (60-80)	70 (60-82)	70 (60-80)	0.84	0
Rhythm (AF), % (N)	46 (215)	66 (37)	43 (178)	0.001	0
BP systolic (mmHg)	139 (126-162)	136 (127-160)	140 (125-162)	0.89	0
BP diastolic (mmHg)	75 (66-83)	74 (66-83)	75 (66-83)	0.63	0
NYHA III/IV, % (N)	22 (103)	43 (24)	19 (79)	< 0.001	0
HeFREF, % (N)	62 (291)	63 (35)	62 (256)	0.37	0
LVEF (%)	45 (35-54)	44 (34-51)	45 (35-54)	0.31	160
Height (m)	1.68 (1.61-1.75)	1.69 (1.60-1.75)	1.68 (1.61-1.75)	0.68	0
Weight (kg)	83 (69-99)	77 (66-89)	83 (69-100)	0.009	0
BMI (kg/m <sup>2</sup> )	29 (25-33)	27 (23-30)	29 (26-33)	0.004	0
Comorbidities					
Charlson score	8 (6-10)	10 (9-12)	8 (6-10)	< 0.001	0
MI, % (N)	42 (198)	38 (21)	43 (177)	0.43	0
PVD, % (N)	15 (72)	25 (14)	14 (58)	0.03	0
HTN, % (N)	67 (313)	66 (37)	67 (276)	0.87	0
CVA, % (N)	15 (71)	23 (13)	14 (58)	0.08	0
Diabetes, % (N)	35 (163)	39 (22)	34 (141)	0.46	0
Dementia, % (N)	10 (48)	36 (20)	7 (28)	< 0.001	0
COPD, % (N)	30 (140)	41 (23)	29 (117)	0.05	0

# Table 1: Baseline characteristics of patients with CHF (Died by 1 year vs alive at 1 year).<sup>1</sup>

Depression, % (N)	20 (93)	29 (16)	19 (77)	0.08	0
Anemia, % (N)	47 (218)	79 (44)	42 (174)	< 0.001	0
Recurrent falls, % (N)	37 (173)	59 (33)	34 (140)	< 0.001	0
Urinary incontinence, % (N)	7 (33)	14 (8)	6 (25)	0.03	0
Medications					
BB, % (N)	84 (392)	79 (44)	85 (348)	0.24	0
ACEi/ARB, % (N)	83 (389)	63 (35)	86 (354)	< 0.001	0
MRA, % (N)	46 (214)	41 (23)	47 (191)	0.45	0
Digoxin, % (N)	21 (100)	32 (18)	20 (82)	0.04	0
Loop diuretic, % (N)	74 (347)	88 (49)	73 (298)	0.02	0
Thiazide, % (N)	4 (17)	4 (2)	4 (15)	0.98	0
$\geq$ 5 medications, % (N)	87 (404)	95 (53)	85 (351)	0.06	0
Blood tests					
NTproBNP (ng/L)	1156 (496-2463)	2507 (1434-5825)	1001 (428-2150)	< 0.001	0
Hb (g/L)	131 (118-142)	117 (106-131)	132 (120-143)	< 0.001	0
Na (mmol/L)	137 (135-138)	136 (133-138)	137 (135-138)	0.04	0
K (mmol/L)	4.4 (4.2-4.7)	4.4 (4.1-4.7)	4.4 (4.2-4.7)	0.40	0
eGFR (mL/min per 1.73m <sup>2</sup> )	55 (40-73)	39 (28-58)	58 (42-74)	< 0.001	0
Malnutrition tools					
CONUT (mal), % (N)	60 (279)	93 (52)	55 (227)	< 0.001	0
GNRI (mal), % (N)	19 (89)	36 (20)	17 (69)	0.001	0
PNI (mal) <sup>2</sup> , % (N)	6 (29)	14 (8)	5 (21)	0.008	0
MUST (mal), % (N)	12 (58)	30 (17)	10 (41)	< 0.001	0
MNA-SF (mal), % (N)	29 (137)	66 (37)	24 (100)	< 0.001	0
SGA (mal), % (N)	21 (100)	54 (30)	17 (70)	< 0.001	0

					_
Cholesterol (mal), % (N)	60 (282)	71 (40)	59 (242)	0.07	0
Albumin (mal), % (N)	25 (116)	59 (33)	20 (83)	< 0.001	0
Lymphocyte (mal), % (N)	44 (203)	63 (35)	41 (168)	0.002	0

HF= heart failure, HR= heart rate, AF= atrial fibrillation, BP= blood pressure, NYHA= new York heart association, HeFREF= heart failure with reduced ejection fraction, LVEF= left ventricular ejection fraction, BMI= body mass index, MI= myocardial infarction, PVD= peripheral vascular disease, HTN= hypertension, CVA= cerebrovascular accident, COPD= chronic obstructive pulmonary disease, BB= beta-blocker, ACEi= angiotensin converting enzyme inhibitor, ARB= angiotensin receptor blocker, MRA= mineralocorticoid receptor antagonist, NTproBNP= N-terminal pro-B-type natriuretic peptide, Hb= hemoglobin, Na= sodium, K= potassium, eGFR = estimated glomerular filtration rate, MaI= malnourished, CONUT = Controlling nutritional status score, GNRI = geriatric nutritional risk index, PNI = prognostic nutritional index, MUST= malnutrition universal screening tool, MNA-SF= mini nutritional assessment –short form, SGA = subjective global assessment.

<sup>1</sup> Continuous data are expressed as a median with interquartile range (IQR) (25<sup>th</sup> to 75<sup>th</sup> centiles) and categorical data are expressed as % (N). Independent t tests and Mann-Whitney U tests were used to compare two continuous variables for normally and non-normally distributed data. The chi-squared test was used to compare proportions between groups.

<sup>2</sup>moderate malnutrition vs no malnutrition (PNI classifies patients as non-malnourished, moderately or severely malnourished)

Woi	rse outcome per unitary						
increase		HR (95% CI)	Wald	Р	HR (95% CI)	Wald	Р
			χ2			χ2	
	Albumin (g/L)	0.87 (0.81,0.93)	14.7	< 0.001	0.90 (0.86,0.95)	18.5	< 0.00
S	Albumin (Mal vs not mal)	2.05 (1.28,3.28)	9.0	0.003	1.96 (1.45,2.65)	18.9	< 0.00
y test	Cholesterol (mmol/L)	0.72 (0.58,0.90)	8.0	0.005	0.91 (0.80,1.03)	2.1	0.15
orator	Cholesterol (Mal vs not mal)	1.64 (1.00,2.69)	3.9	0.05	1.27 (0.95,1.70)	2.5	0.11
Laboratory tests	Lymphocyte (x10 <sup>9</sup> /L)	0.89 (0.61,1.30)	0.4	0.55	0.91 (0.73,1.14)	0.7	0.41
	Lymphocyte (Mal vs not mal)	0.99 (0.62,1.58)	0.001	0.97	0.94 (0.70,1.25)	0.2	0.66
	CONUT	1.28 (1.13,1.45)	15.4	< 0.001	1.23 (1.13,1.34)	23.5	<0.00
	CONUT (Mal vs not mal)	3.05 (1.58,5.85)	11.2	0.001	1.52 (1.10,2.11)	6.3	0.01
le	GNRI	0.98 (0.96,1.00)	4.9	0.03	0.99 (0.97,1.00)	5.9	0.02
Simple	GNRI (Mal vs not mal)	1.18 (0.69,2.02)	0.4	0.55	1.84 (1.31,2.59)	12.4	<0.00
	PNI	0.92 (0.88,0.98)	8.4	0.004	0.95 (0.92,0.98)	10.7	0.00
	$PNI \; (Mal \; vs \; not \; mal)^2$	1.45 (0.73,2.88)	1.1	0.29	2.18 (1.36,3.48)	10.6	0.00
Σ	MUST	1.38 (1.03,1.84)	4.6	0.03	1.27 (1.05,1.53)	5.8	0.02

Table 2: Multivariable Cox proportional hazards regression analyses of malnutrition tools predicting all-cause mortality and combined outcome.<sup>1</sup>

MUST (Mal vs not mal)	1.32 (0.74,2.33)	0.9	0.35	2.01 (1.38,2.95)	13.0	< 0.001
MNA-SF	0.84 (0.75,0.93)	10.2	0.001	0.85 (0.79,0.91)	21.2	< 0.001
MNA-SF (Mal vs not mal)	2.09 (1.26,3.47)	8.2	0.004	2.12 (1.55,2.90)	21.9	< 0.001
SGA	1.83 (1.12,3.00)	5.8	0.02	1.97 (1.41,2.76)	15.9	< 0.001
SGA (Mal vs not mal)	2.06 (1.10,3.88)	5.1	0.03	2.37 (1.58,3.54)	17.6	< 0.001

Mal= malnourished, CONUT = Controlling nutritional status score, GNRI = geriatric nutritional risk index, PNI = prognostic nutritional index, MUST= malnutrition universal screening tool, MNA-SF= mini nutritional assessment –short form, SGA = subjective global assessment.

<sup>1</sup>Separate multivariable analysis was performed for each tool as both binary and continuous variable, with Supplementary Table 3 showing clinical variables included in multivariable analysis for predicting all-cause mortality and combined outcome. No significant interactions were found between variables included in the multivariable Cox regression models

<sup>2</sup>moderate malnutrition vs no malnutrition (PNI classifies patients as non-malnourished, moderately or severely malnourished)

<sup>3</sup> Variables in multivariable analysis predicting all-cause mortality included: Age, BMI, AF vs sinus rhythm, NYHA (III/IV vs I/II), Charlson score, log[NT-proBNP], Hb, eGFR. (BMI is not included in multivariable analysis involving MNA-SF, GNRI or MUST as it is part of these scores).

<sup>4</sup> Variables in multivariable analysis predicting combined outcome included: Age, BMI, NYHA (III/IV vs I/II), Charlson score, log[NTproBNP], Hb, eGFR (AF vs sinus rhythm is not included as it is not a significant predictor of combined outcome in univariable analysis; BMI is not included in multivariable analysis involving MNA-SF, GNRI or MUST as it is part of these scores). Table 3: Addition of malnutrition tools and its impact on performance of base model containing age, NYHA (III/IV vs I/II), Log [NTproBNP], Hb, eGFR, atrial fibrillation, CVA and COPD in predicting all-cause mortality.<sup>1</sup>

Model	C-statistics (95% CI)					
		Compared to base model				
		(P value)				
Base model <sup>2</sup>	0.757 (0.71, 0.81)	-				
$Base^2 + BMI$	0.760 (0.71, 0.81)	0.27				
Simple tools						
$Base^2 + CONUT$	0.777 (0.73, 0.83)	0.0001				
$Base^2 + GNRI$	0.766 (0.71, 0.82)	0.009				
$Base^2 + PNI$	0.770 (0.72, 0.82)	0.0007				
Multi-dimensional tools						
$Base^2 + MUST$	0.762 (0.71, 0.82)	0.02				
$Base^2 + MNA-SF$	0.776 (0.72, 0.83)	0.0003				
$Base^2 + SGA$	0.768 (0.71, 0.82)	0.002				
Single tests						
$Base^2 + Cholesterol$	0.767 (0.72, 0.82)	0.003				
$Base^2 + Albumin$	0.773 (0.72, 0.82)	< 0.001				
Base <sup>2</sup> + Total lymphocyte count	0.758 (0.71, 0.81)	0.44				


AF= atrial fibrillation, SR= sinus rhythm, NYHA= New York Heart Association, NT-proBNP= N-terminal pro-B-type natriuretic peptide, Hb= hemoglobin, eGFR = estimated glomerular filtration rate, CVA= cerebrovascular accident, COPD= chronic obstructive pulmonary disease, CONUT = Controlling nutritional status score, GNRI = geriatric nutritional risk index, PNI = prognostic nutritional index, MUST= malnutrition universal screening tool, MNA-SF= mini nutritional assessment –short form, SGA = subjective global assessment, CI= confidence interval.


<sup>1</sup>Harrell's C-statistic was used to evaluate model discrimination in survival analyses. The likelihood ratio test was used to determine if there was any significant difference in model fit between the base model and models including different malnutrition tools.


<sup>2</sup> Base model: Age, NYHA (III/IV vs I/II), Log [NTproBNP], Rhythm (AF vs SR), Hb, eGFR, CVA, COPD

### **Figure Legend**

Figure 1: Kaplan Meier curves illustrating the relation between malnutrition tools and allcause mortality (Top panel: simple tools; middle panel: multi-dimensional tools; bottom panel: single laboratory tests). Log rank test was used to compare survival between groups. Figure 2: 3 month, 6 month & 12 month mortality (top panel) and combined event rates (bottom panel) according to malnutrition categories of the CONUT score, MNA-SF and serum albumin level. The chi-squared test was used to compare proportions between groups. Figure 3: Kaplan Meier curves illustrating the relation between malnutrition tools and combined outcome (Top panel: simple tools; middle panel: multi-dimensional tools; bottom panel: single laboratory tests). Log rank test was used to compare survival between groups.







A, All-cause mortality

CONUT

Albumin

**MNA-SF** 

¢	ц				<0.001	<0.001	<0.001
4	$\wedge$	2	≤ 30	N=17	18% (N=3)	29% (N=5)	47% (N=8)
	Inutrition		31-34	06=N	4% (N=4)	13% (N=13)	25% (N=25)
Worsening malnutrition			35-39	N=276	0 (N=1)	2% (N=5)	7% (N=20)
	Wors		≥ 40	N=75	0	3% (N=2)	4% (N=3)
					w £	<b>w</b> 9	u 21
þ	4				<0.001	<0.001	<0.001
4	$\wedge$	$\geq$	8 VI	N=30	13% (N=4)	23% (N=7)	33% (N=10)
	Worsening malnutrition		9-10	N=61	7% (N=4)	18% (N=11)	32% (N=20)
		ening ma	11-12	N=132	0	4% (N=5)	11% (N=15)
			13-14	N=241	0	0 (N=1)	4% (N=10)
					ш ғ	ш 9	ա շլ
D	4				<0.001	<0.001	<0.001
2		2	<u>&gt;</u> 6	N=22	9% (N=2)	18% (N=4)	36% (N=8)
	nutrition	nutrition	4-5	N=68	6% (N=4)	19% (N=13)	28% (N=19)
	Worsening malnutrition		2-3	N=190	1% (N=2)	4% (N=8)	13% (N=25)
	Worse		0-1	N=187	0	0	2% (N=4)
					u ç	ш <u>9</u>	ա շլ

Mortality Rate:  $\Box < 5\%$   $\Box 5-10\%$   $\Box 10-20\%$   $\Box 20-50\%$ 

B, Combined event rates

												_
	٩	4				<0.001		<0.001		<0.001		
	4		7	≤ 30	N=17	47%	(N=8)	71%	(N=12)	82%	(N=14)	
min		alnutritio		31-34	06=N	19%	(N=19)	39%	(N=39)	60%	(N=59)	
Albumin		Worsening malnutrition		35-39	N=276	11%	(N=31)	19%	(N=53)	29%	(6/=N)	
		Wor		≥40	N=75	8%	(N=6)	12%	(N=9)	23%	(N=17)	>70%
						u	1 £	u	19	u	121	%0
	ط	4				<0.001		<0.001		<0.001		□ <10% □ 10-20% □ 21-40% □ 41-70% □ >70%
	4	$\wedge$	2	× 8	(N=30)	27%	(N=8)	57%	(N=17)	73%	(N=22)	21-409
MNA-SF		nutrition		9-10	(N=61)	38%	(N=23)	61%	(N=37)	71%	(N=43)	■ %(
M		Worsening malnutrition		11-12	(N=132)	15%	(N=20)	27%	(N=35)	36%	(N=48)	10-2(
		Wors		13-14	(N=241)	5%	(N=13)	10%	(N=23)	22%	(N=54)	<10%
						u	ı £	u	19	u	121	
	-	ч				<0.001		<0.001		<0.001		Combined event rate:
	2		2	≥6	N=22	32%	(L=N)	73%	(N=16)	82%	(N=18)	ombined
CONUT		alnutritio		4-5	N=68	2.8%	(N=19)	50%	(N=34)	68%	(N=46)	Ŭ
<u> </u>		Worsening malnutrition		2-3	N=190	12%	(N=23)	20%			(N=60)	
		Wor		0-1	N=187	8%	(N=15)	13%	(N=25)		(N=45)	
						ι	n £	ι	u 9	U	u 21	

